纳米载药系统靶向肿瘤干细胞的研究进展

doi:10.11904/j.issn.1002-3070.2019.03.016

摘要/Abstract

摘要： 癌症是严重危害人类身体健康的主要疾病之一,经传统治疗后仍可能出现复发和转移,其根本原因是肿瘤组织中存在肿瘤干细胞(CSCs)。CSCs具有高度增殖、自我更新、多向分化、高度致瘤和多重耐药性等特征,控制着肿瘤的发生发展、化疗耐受、复发和转移等过程。因此,清除CSCs是提高癌症治愈率的有效方法之一。纳米载体具有尺寸小、比表面积大、生物相容性好、可体内降解等多项优点,常被用于靶向递送和缓释药物,为克服传统化疗药物的毒副作用、避免手术机械损伤和杀灭CSCs提供了可能。本文将对CSCs和纳米载药系统的特点,以及近年来纳米载药系统在CSCs中的研究进展做一综述。

关键词: 纳米载药系统, 肿瘤干细胞, 靶向治疗

Abstract: Cancer is one of the major diseases that seriously endanger human health.Recurrence and metastasis may still occur after traditional treatment.The basic reason is the presence of cancer stem cells(CSCs)in tumor tissues.CSCs have a high degree of proliferative ability,self-renewal,multi-directional differentiation,highly tumorigenicity and multi-drug resistance,which control the occurrence and development of tumors,chemotherapy tolerance,recurrence and metastasis.Therefore,clearing CSCs is one of effective ways to improve the curative rate of cancer.Nano-carriers have many advantages such as small size,large specific surface area,good biocompatibility and degradation in vivo.They are often used for targeted delivery and sustained release of drugs,which overcome the toxic side effects of traditional chemotherapeutic drugs,avoid surgical damage and kill CSCs.This paper will review the characteristics of CSCs and nano drug-loading systems as well as their research progress of nano drug-loading systems in CSCs in recent years.

Key words: Nano-drug delivery system, Cancer stem cell, Targeted therapy

中图分类号:

朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.

ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.

参考文献

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
2 陈万青,李贺,孙可欣,等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2018,40(1):5-13.
3 Al-Hajj M,Wicha MS,Benito-Hernandezt A,et al.Prospective identification of tumorigenic breast cancer cells[J].P Natl Acad Sci USA,2003,100(7):3983-3988.
4 Cao S,Wang Z,Gao X,et al.FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC[J].J Exp Clin Cancer Res,2018,37(1):220.
5 Zhang Y,Zhang Q,Sun J,et al.The combination therapy of salinomycin and gefitinib using poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol)nanoparticles for targeting both lung cancer stem cells and cancer cells[J].Onco Targets Ther,2017,10:5653-5666.
6 Yang Y,Meng Q,Wang C,et al.MicroRNA 675 cooperates PKM2 to aggravate progression of human liver cancer stem cells induced from embryonic stem cells[J].J Mol Med,2018,96(10):1119-1130.
7 Aliebrahimi S,Kouhsari SM,Arab SS,et al.Phytochemicals,withaferin A and carnosol,overcome pancreatic cancer stem cells as c-Met inhibitors[J].Biomed Pharmacother,2018,106:1527-1536.
8 Kumar D,Gorain M,Kundu G,et al.Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma[J].Mol Cancer,2017,16(1):7.
9 李韶静,廖应芬,杜青.槲皮素纳米载药系统的研究与应用[J].中国中药杂志,2018,43(10):1978-1984.
10 Ajani JA,Song S,Hochster HS,et al.Cancer stem cells:The promise and the potential[J].Semin Oncol,2015,42:3-17.
11 崔畅畅,柯学,吕慧侠.肿瘤干细胞靶向治疗研究进展[J].药学进展,2016,40(1):20-29.
12 曹棉富,周代君,嘉桑摇,等.肿瘤干细胞的靶向治疗策略[J].医学研究生学报,2012,25(8):886-888.
13 何勤,刘亚圆.肿瘤靶向纳米载药系统的设计与构建[J].药学进展,2016,40(4):261-269.
14 訚亚涛,彭英.纳米载体在胶质瘤治疗中的研究进展[J].国际神经病学神经外科学杂志,2014,41(3):242-245.
15 杜锐凯,柳素玲.利用纳米技术靶向肿瘤干细胞的研究进展[J].科学通报,2015(35):3417-3423.
16 郭杏,冯雁,黄馨萍,等.代谢重编程及其与消化系统恶性肿瘤关系的研究进展[J].山东医药,2018,58(12):98-101.
17 Shen Y,Li W,Chen P,et al.Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol?-resistant ovarian cancer[J].Am J Transl Res,2015,7(5):841-855.
18 Liu Y,Mei L,Yu Q,et al.Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma[J].Acs Appl Mater Inter,2015,7(30):16792-16801.
19 Paula AD,Lopes C.Implications of different cancer stem cell phenotypes in breast cancer[J].Anticancer Res,2017,37(5):2173-2183.
20 Zhu Z,Hao X,Yan M,et al.Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma[J].Int J Cancer,2010,126(9):2067-2078.
21 Damelin M,Geles KG,Follettie MT,et al.Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells[J].Cancer Res,2011,71(12):4236-4246.
22 Leung EL,Fiscus RR,Tung JW,et al.Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties[J].PLoS One,2010,5(11):e14062.
23 Takaishi S,Okumura T,Tu S,et al.Identification of gastric cancer stem cells using the cell surface marker CD44[J].Stem Cells,2009,27(5):1006-1020.
24 Han N,Shin DH,Kim JS,et al.Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells[J].Int J Nanomed,2016,11:1413-1425.
25 Zhao P,Dong S,Bhattacharyya J,et al.iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors[J].Mol Pharmaceut,2014,11(8):2703-2712.
26 Wang X,Low XC,Hou W,et al.Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells[J].Acs Nano,2014,8(12):12151-12166.
27 Jang E,Kim E,Son H,et al.Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy[J].Biomaterials,2016,105:12-24.
28 王江峰,鲁莹,钟延强.聚氨基酯作为基因载体的研究进展[J].药学实践杂志,2011,29(3):165-168.
29 Lopez-Bertoni H,Kozielski KL,Rui Y,et al.Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival[J].Nano Lett,2018,18(7):4086-4094.
30 Cui F,Liu Q,Li R,et al.Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells[J].Int J Nanomed,2014,9:2345-2358.
31 Kim S,Rait A,Kim E,et al.A Nanoparticle Carrying the p53 gene targets tumors including cancer stem cells,sensitizes glioblastoma to chemotherapy and improves survival[J].Acs Nano,2014,8(6):5494-5514.
32 Islam F,Gopalan V,Wahab R,et al.Cancer stem cells in oesophageal squamous cell carcinoma:Identification,prognostic and treatment perspectives[J].Crit Rev Oncol Hemat,2015,96(1):9-19.
33 Roudi R,Korourian A,Shariftabrizi A,et al.Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes[J].Cancer Invest,2015,33(7):294-302.
34 Jing F,Kim HJ,Kim CH,et al.Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases[J].Int J Oncol,2015,46(4):1582-1588.
35 Wei X,He J,Wang J,et al.MPEG-CS/Bmi-1RNAi nanoparticles synthesis and its targeted inhibition effect on CD133+ laryngeal stem cells[J].J Nanosci Nanotechno,2018,18(3):1577-1584.
36 Sun R,Liu Y,Li S,et al.Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells[J].Biomaterials,2015,37:405-414.
37 Muntimadugu E,Kumar R,Saladi S,et al.CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel[J].Colloids and surfaces B:Biointerfaces,2016,143:532-546.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[3]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.
[4]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[5]	黄倩倩, 马建加, 吴强, 刘彬彬, 沐晓芹, 刘树林审校. 肿瘤干细胞及肿瘤靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 533-537.
[6]	黄承路, 韩少辉徐苏琴综述, 赵俊刚审校. 原发性肺黏液腺癌的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 463-467.
[7]	孙禹琪,陈秀玮. CTGF/CCN2在恶性肿瘤的发生发展及靶向治疗中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 363-366.
[8]	左志超, 苏丹柯, 邓文娟综述, 金观桥审校. ELAM-1在肿瘤靶向治疗中的应用进展[J]. 实用肿瘤学杂志, 2016, 30(5): 444-447.
[9]	赵相轩, 温锋, 毛晓楠综述, 卢再鸣审校. 细胞凋亡在原发性肝癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 448-452.
[10]	赵相轩,温锋综述,卢再鸣审校. 细胞凋亡在胰腺癌治疗中的作用[J]. 实用肿瘤学杂志, 2016, 30(4): 375-379.
[11]	刘伟综述, 李惠艳审校. 表皮生长因子受体与放射敏感性关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 275-278.
[12]	潘夏综述, 江建平审校. Alectinib在非小细胞肺癌治疗中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 75-79.
[13]	吕福莲, 高翔综述, 金艾顺审校. 肿瘤干细胞潜在标志物DCLK1在消化道恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(5): 458-461.
[14]	张佳文, 曹京燕, 金时综述, 于雁审校. Hsp90抑制剂NVP-AUY922单药及联合用药在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(3): 284-288.
[15]	刘恩瑞,任欢,赵宇(综述),苏君(审校). 胶质母细胞瘤经典亚型特征性基因变异的研究进展[J]. 实用肿瘤学杂志, 2015, 29(2): 136-139.